By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA

Company News
Ariad (ARIA) To Webcast Conference Call On First Quarter 2016 Financial Results 4/26/2016 12:08:07 PM
Ariad (ARIA) Announces Results Of Preclinical Studies On AP32788 At The Annual Meeting Of AACR 4/19/2016 11:37:14 AM
Ariad (ARIA) Presents Updated Phase 1/2 Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/15/2016 9:29:01 AM
Struggling Ariad (ARIA)'s Luck Might be Turning Around as Company Eyes Pfizer (PFE)'s ALK Space 4/12/2016 8:41:40 AM
Ariad (ARIA) Announces Initiation Of Randomized, First-Line Phase 3 Trial Of Brigatinib In Treatment Of Alk-Positive Non-Small Cell Lung Cancer 4/11/2016 11:12:03 AM
Ariad (ARIA) Cuts Another 25% of Workforce at HQ 3/29/2016 11:58:23 AM
Ariad (ARIA) Reports Inducement Grant To New Chief Financial Officer 3/22/2016 11:53:16 AM
Ariad (ARIA) Taps Former Pharmacyclics (PCYC) Exec as New CFO 3/11/2016 5:49:16 AM
Ariad (ARIA) To Present At Upcoming Investor Conferences 2/29/2016 11:25:00 AM
Ariad (ARIA)'s New CEO Hinted at Cost Cuts and Potential M&As in First Call with Investors 2/25/2016 5:59:44 AM